[go: up one dir, main page]

FI935970L - Tumoer/kolhydratantigenspecifik monoklonal antikropp samt cellinje - Google Patents

Tumoer/kolhydratantigenspecifik monoklonal antikropp samt cellinje Download PDF

Info

Publication number
FI935970L
FI935970L FI935970A FI935970A FI935970L FI 935970 L FI935970 L FI 935970L FI 935970 A FI935970 A FI 935970A FI 935970 A FI935970 A FI 935970A FI 935970 L FI935970 L FI 935970L
Authority
FI
Finland
Prior art keywords
tumoer
kolhydratantigenspecifik
cellinje
samt
antikropp
Prior art date
Application number
FI935970A
Other languages
English (en)
Other versions
FI935970A0 (fi
FI109207B (fi
Inventor
Leif Lindholm
Jan Holmgren
Peter Lind
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of FI935970A0 publication Critical patent/FI935970A0/fi
Publication of FI935970L publication Critical patent/FI935970L/fi
Application granted granted Critical
Publication of FI109207B publication Critical patent/FI109207B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI935970A 1991-07-03 1993-12-31 Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja FI109207B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody
SE9102074 1991-07-03
SE9200502 1992-07-03
PCT/SE1992/000502 WO1993001303A1 (en) 1991-07-03 1992-07-03 Tumor, carbohydrate antigen specific monoclonal antibody and cell line

Publications (3)

Publication Number Publication Date
FI935970A0 FI935970A0 (fi) 1993-12-31
FI935970L true FI935970L (fi) 1993-12-31
FI109207B FI109207B (fi) 2002-06-14

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935970A FI109207B (fi) 1991-07-03 1993-12-31 Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja

Country Status (19)

Country Link
US (1) US5552293A (fi)
EP (1) EP0521842B1 (fi)
JP (1) JP3194020B2 (fi)
KR (1) KR100246681B1 (fi)
AT (1) ATE171193T1 (fi)
AU (2) AU658198B2 (fi)
CA (1) CA2073124C (fi)
DE (1) DE69226990T2 (fi)
DK (1) DK0521842T3 (fi)
EE (1) EE03031B1 (fi)
ES (1) ES2124250T3 (fi)
FI (1) FI109207B (fi)
HU (2) HU218084B (fi)
IE (1) IE80841B1 (fi)
IL (1) IL102390A (fi)
NO (1) NO315472B1 (fi)
NZ (1) NZ243435A (fi)
SE (1) SE9102074D0 (fi)
WO (2) WO1993001302A1 (fi)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
PT970126E (pt) * 1997-04-14 2001-10-30 Micromet Ag Novo metodo para a producao de receptores de antigenios anti-humanos e suas utilizacoes
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP2295064B1 (en) * 2001-03-15 2017-02-22 Precision Biologics, Inc. Monoclonal antibody therapy for pancreas cancer
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
NZ537610A (en) * 2002-07-02 2006-07-28 Smithkline Beecham Corp Stable formulations of the C242 antibody
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CA2525130C (en) 2003-05-20 2014-04-15 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
EP2468304A3 (en) 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
NZ595387A (en) * 2005-08-11 2013-04-26 Arpi Matossian Rogers Peptides for treatment and diagnosis of autoimmune disease
AU2012244244B2 (en) * 2005-08-11 2015-08-27 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
CA2893252C (en) 2005-08-24 2018-05-29 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
CN102171570B (zh) 2008-08-05 2014-10-15 东丽株式会社 用于检测癌的方法
KR102444399B1 (ko) 2009-06-03 2022-09-16 이뮤노젠 아이엔씨 메이탄시노이드의 제조방법
SG193996A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
CN107537040A (zh) 2011-03-29 2018-01-05 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
AU2015349985A1 (en) 2014-11-19 2017-05-25 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
US10314910B2 (en) 2016-01-10 2019-06-11 Neotx Therapeutics Ltd. Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
CA3013125A1 (en) 2016-02-05 2017-08-10 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
WO2019035034A1 (en) * 2017-08-16 2019-02-21 The Broad Institute, Inc. NEURONAL DOSAGE METHOD INVOLVING CALCINEURIN
JP2022531978A (ja) 2019-05-15 2022-07-12 ネオティーエックス セラピューティクス リミテッド 癌治療
KR20220150353A (ko) 2020-03-05 2022-11-10 네오티엑스 테라퓨틱스 엘티디. 면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
JP3334130B2 (ja) * 1990-07-20 2002-10-15 フアルマシア・アクチエボラーグ 抗体接合体
WO1992001474A1 (en) * 1990-07-20 1992-02-06 Kabi Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures

Also Published As

Publication number Publication date
ATE171193T1 (de) 1998-10-15
IE80841B1 (en) 1999-03-24
US5552293A (en) 1996-09-03
JP3194020B2 (ja) 2001-07-30
AU1942592A (en) 1993-01-07
DK0521842T3 (da) 1999-06-14
ES2124250T3 (es) 1999-02-01
NO934777D0 (no) 1993-12-22
HU211512A9 (en) 1995-11-28
NZ243435A (en) 1994-10-26
WO1993001302A1 (en) 1993-01-21
SE9102074D0 (sv) 1991-07-03
HU9400011D0 (en) 1994-05-30
NO934777L (no) 1994-02-11
FI935970A0 (fi) 1993-12-31
AU2292092A (en) 1993-02-11
EP0521842B1 (en) 1998-09-16
JPH05276987A (ja) 1993-10-26
IL102390A0 (en) 1993-01-14
HU218084B (hu) 2000-05-28
IL102390A (en) 1996-01-19
FI109207B (fi) 2002-06-14
AU658198B2 (en) 1995-04-06
IE922188A1 (en) 1993-01-13
EE03031B1 (et) 1997-08-15
HUT71193A (en) 1995-11-28
DE69226990D1 (de) 1998-10-22
DE69226990T2 (de) 1999-03-25
EP0521842A3 (fi) 1994-01-26
CA2073124C (en) 2007-06-19
EP0521842A2 (en) 1993-01-07
NO315472B1 (no) 2003-09-08
WO1993001303A1 (en) 1993-01-21
CA2073124A1 (en) 1993-01-04
KR100246681B1 (ko) 2000-04-01

Similar Documents

Publication Publication Date Title
FI935970L (fi) Tumoer/kolhydratantigenspecifik monoklonal antikropp samt cellinje
FI935118A7 (fi) Stabiliserad resonanskretsetikett samt en deaktiverare
FI924033L (fi) Omslag foer roekningsprodukt foer reglering av foerbraenningshastigheten samt foerfarande foer framstaellning av detsamma
FI921554A7 (fi) Anordning foer gjutning av plastfolie samt anvaendning av densamma
FI925409A7 (fi) Foerfarande foer framstaellning av halvledarkomponenter samt en solcell framstaellt daerav
FI924963L (fi) Staerkelsefibrer, foerfarande foer deras framstaellning samt deras anvaendning
FI921917L (fi) Gelemassor samt deras framstaellning och anvaendning
FI930580L (fi) Tri- och tetravalensiska monopecifika antigen bindande proteiner
FI923531L (fi) Papper foer saekerhetshandlingar med foerbaettrad tryckbarhet samt omloppshaollbarhet.
FI932999A7 (fi) Foerfarande foer lageravdragning, lageravdragare samt anvaendning daerav
FI924141A7 (fi) Optisk kommutator samt dess tilverkningsfoerfarande
FI923342L (fi) Pleuromutilinkomplex
FI933807A7 (fi) Digital faskomparator samt en fasregleringskrets
FI920574L (fi) Tillsatsmedel foer sprutbetong och -bruk samt foerfarande foer tillverkning av sprutbetong och -bruk under anvaendning av tillsatsmedlet
FI935562L (fi) Utportioneringsanordning foer flytande substanser samt inraettning innefattande saodan anordning
FI920978L (fi) Foerfarande samt anordning foer att torka bestrukna banor
FI932720L (fi) Barriaerfilm samt foerfarande foer framstaellning daerav
FI922681L (fi) Nytt foerpacknings/behaollarsystem
FI934395L (fi) 2-spirocyklopropyl 4-acylcephemi samt foerfarande foer framstaellning daerav
FI923440A7 (fi) 6-oxo-azepinoindolfoereningar samt foerfaranden och mellanprodukter foer deras framstaellning
FI910769L (fi) Foerfarande foer foerminskning av startstroem av en kortsluten asynkronmotor samt en foer tillaempning av foerfarandet avsedd kortsluten asynkronmotorenhet
FI933408L (fi) Ksylanas, ksylanas producerande bacillus-stammar samt deras utnyttjande
FI934447L (fi) Nytt immunhaemmande aemne fraon strptomyces braegensis
FI934396L (fi) 2-spirocyklopropyl cefalosporinsulfonderivat samt foerfarande foer framstaellning daerav
FI922683L (fi) Nytt foerpacknings/behaollarsystem

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: PHARMACIA AB

MA Patent expired